Phase 3 N=32 Randomized Treatment

Spasmodic Dysphonia Pain

Spasmodic Dysphonia

Bottom Line

View on ClinicalTrials.gov: NCT04648891 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2024

Primary outcome: Primary: Pain Experienced — 2; 2; 2 score on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: Lidocaine (Drug); Vibrating wand (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Mayo Clinic
Primary completion: Jul 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Pain Experienced	2; 2; 2	—
SECONDARY Subject Preference	6; 12; 14	—

Summary

This study aims to identify adjuvant methods to improve patient comfort during in-office laryngology procedures.

Eligibility Criteria

Inclusion Criteria

Spasmodic dysphonia with or without tremor
Receiving botox as treatment via a transcricothyroid approach

Exclusion Criteria

Allergy to lidocaine

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04648891). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.